Literature DB >> 8427753

Iodixanol in cardioangiography in patients with coronary artery disease. Tolerability, cardiac and renal effects.

N E Kløw1, K Levorstad, K J Berg, U Brodahl, K Endresen, D T Kristoffersen, B Laake, S Simonsen, A J Tofte, B Lundby.   

Abstract

Iodixanol is a new nonionic, dimeric contrast medium. With the addition of 18 mmol/l Na+ and 0.3 mmol/l Ca++ to iodixanol 320 mg I/ml a plasma-isotonic solution was obtained. The purpose was to evaluate the suitability of iodixanol for use in cardioangiography by determining the diagnostic efficacy, patient tolerability, and cardiac and renal side-effects. Initially, 14 patients with coronary artery disease were examined using iodixanol. A double-blind, randomized study was then performed in 72 patients, comparing iodixanol and iohexol. Serum and urine were sampled before the examination, and one and 2 days after. The diagnostic information was good and the number of adverse events low with iodixanol. The patients reported significantly less of a sensation of warmth following injection of iodixanol than iohexol. Our results also indicate that iodixanol 320 mg I/ml influences renal function to a lesser degree than does iohexol 350 mg I/ml. We therefore conclude that isotonic iodixanol is a safe contrast medium for use in cardioangiography.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8427753

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  10 in total

1.  Effects of Intra-Arterial and Intravenous Iso-Osmolar Contrast Medium (Iodixanol) on the Risk of Contrast-Induced Acute Kidney Injury: A Meta-Analysis.

Authors:  Peter A McCullough; Jeremiah R Brown
Journal:  Cardiorenal Med       Date:  2011-10-04       Impact factor: 2.041

2.  Renal experience with Visipaque.

Authors:  J A Jakobsen
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

Review 3.  The non-ionic isotonic contrast agents. Perspectives and controversies.

Authors:  P Dawson
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

Review 4.  [Anesthesiological management of neuroendovascular interventions].

Authors:  H Preiss; J Reinartz; S Lowens; H Henkes
Journal:  Anaesthesist       Date:  2006-06       Impact factor: 1.041

5.  Intra-arterial digital subtraction angiography with isotonic dimeric (iodixanol) and monomeric (iohexol) nonionic contrast media: radiographic, clinical and neurophysiological evaluation.

Authors:  R E Hekster; H H Morré; P Cleyndert; J Zapletal; L F Sinnige; B Bolstad; Y Keetlapper
Journal:  Neuroradiology       Date:  1995-01       Impact factor: 2.804

6.  Patient discomfort associated with the use of intra-arterial iodinated contrast media: a meta-analysis of comparative randomized controlled trials.

Authors:  Peter A McCullough; Patrizio Capasso
Journal:  BMC Med Imaging       Date:  2011-05-24       Impact factor: 1.930

Review 7.  Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology.

Authors:  Stanley Goldfarb; Peter A McCullough; John McDermott; Spencer B Gay
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

8.  Iodixanol in intra-arterial cerebral digital subtraction angiography: a comparison with iohexol.

Authors:  B E Kendall; A Sheppick; J O Nossen; J M Stevens
Journal:  Neuroradiology       Date:  1995-10       Impact factor: 2.804

9.  Iodixanol vs iopamidol in intravenous DSA of the abdominal aorta and lower extremity arteries: a comparative phase-III trial.

Authors:  R Fischbach; P Landwehr; K Lackner; J O Nossen; W Heindel; K J Berg; G Eichhorn; T F Jacobsen
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

10.  Production of adeno-associated virus vectors for in vitro and in vivo applications.

Authors:  Toyokazu Kimura; Beatriz Ferran; Yuko Tsukahara; Qifan Shang; Suveer Desai; Alessandra Fedoce; David Richard Pimentel; Ivan Luptak; Takeshi Adachi; Yasuo Ido; Reiko Matsui; Markus Michael Bachschmid
Journal:  Sci Rep       Date:  2019-09-19       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.